Postoperative cardiac troponin I (cTnI) level and its prognostic value for patients undergoing mitral valve surgery

Kiyohiro Oshima1, Fumio Kunimoto, Toru Takahashi

  • 1Intensive Care Unit, Gunma University Hospital, Gunma, Japan.

Insights

Postoperative cardiac troponin I (cTnI) levels, measured on POD 1 and 2, better predict intensive care unit (ICU) and hospital stay after mitral valve surgery than creatine kinase-myocardial band (CK-MB) levels.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Biomarkers

Background:

  • Cardiac troponin I (cTnI) predicts outcomes after cardiac surgery, but data is limited to heterogeneous patient groups.
  • Elevated cTnI levels are linked to increased in-hospital mortality in cardiac surgery patients.

Purpose of the Study:

  • To determine the predictive value of postoperative cTnI for patient outcomes specifically in mitral valve surgery.
  • To compare the efficacy of cTnI with creatine kinase-myocardial band (CK-MB) in predicting postoperative course.

Main Methods:

  • Retrospective analysis of 24 mitral valve surgery patients (July 2004-April 2009).
  • Serum cTnI and CK-MB levels measured on postoperative days (POD) 0, 1, 2, and 3.
  • Evaluation of correlations between biomarker levels, cardiopulmonary bypass (CPB) time, aorta cross-clamping (AoC) time, ICU stay, and postoperative hospital stay (POHS).

Main Results:

  • Cardiopulmonary bypass (CPB) and aorta cross-clamping (AoC) times influenced postoperative cTnI and CK-MB levels.
  • cTnI levels on POD 1 and POD 2 significantly correlated with ICU stay duration.
  • cTnI levels on POD 1 and POD 2 significantly correlated with POHS, unlike CK-MB levels.

Conclusions:

  • Postoperative cTnI measurements are more effective than CK-MB in predicting the postoperative course following mitral valve surgery.
  • cTnI serves as a valuable prognostic biomarker for patients undergoing mitral valve repair or replacement.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...